Luz Castillo
- Marketing Promotions - Public Relations - Business Development - Account Management - Presentations - Strategic Planning - Research - Event Coordination - Social Media
In October, 2023 Lung Therapeutics was acquired by Aileron Therapeutics. Aileron is now a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit https://aileronrx.com
